Whole-genome analysis informs breast cancer response to aromatase inhibition

Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, Jeremy Hoog, Reece J. Goiffon, Theodore C. Goldstein, Sam Ng, Li Lin, Robert Crowder, Jacqueline Snider, Karla Ballman, Jason Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William S. SchierdingJoshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher C. Harris, Michael D. McLellan, Michael C. Wendl, Katherine Deschryver, D. Craig Allred, Laura Esserman, Gary Unzeitig, Julie Margenthaler, G. V. Babiera, P. Kelly Marcom, J. M. Guenther, Marilyn Leitch, Kelly Hunt, John Olson, Yu Tao, Christopher A. Maher, Lucinda L. Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica-Worms, Sandra McDonald, Mark Watson, David J. Dooling, David Ota, Li Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica-Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis

Research output: Contribution to journalArticle

692 Scopus citations

Abstract

To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to haematopoietic disorders. Mutant MAP3K1 was associated with luminal A status, low-grade histology and low proliferation rates, whereas mutant TP53 was associated with the opposite pattern. Moreover, mutant GATA3 correlated with suppression of proliferation upon aromatase inhibitor treatment. Pathway analysis demonstrated that mutations in MAP2K4, a MAP3K1 substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated with specific patterns of somatic mutations that map into cellular pathways linked to tumour biology, but most recurrent mutations are relatively infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing.

Original languageEnglish (US)
Pages (from-to)353-360
Number of pages8
JournalNature
Volume486
Issue number7403
DOIs
StatePublished - Jun 21 2012

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Whole-genome analysis informs breast cancer response to aromatase inhibition'. Together they form a unique fingerprint.

  • Cite this

    Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., Ng, S., Lin, L., Crowder, R., Snider, J., Ballman, K., Weber, J., Chen, K., Koboldt, D. C., Kandoth, C., ... Mardis, E. R. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353-360. https://doi.org/10.1038/nature11143